Introduction
The growth and differentiation of hematopoietic cells is regulated by a number of cytokines, in vitro and in vivo. HL-60, a human promyelocytic cell line, has been used extensively as an in vitro model for studying the effects of factors which regulate growth and differentiation of hematopoietic cells in general, and of myeloid leukemia cells in particular 1 . These cells proliferate
as promyelocytes yet retain the capacity to undergo terminal myeloid or monocytic differentiation in response to various inducing agents. In the presence of all-trans-retinoic acid (ATRA), HL-60 cells undergo differentiation to granulocytes, while 1 ,25(OH) 2 . Other studies showing that induction of terminal differentiation by retinoids and Vit D 3 requires TGF-1 as an autocrine mediator suggest that endogenous TGF-1 plays a critical role in the differentiation of leukemia cells [8] [9] [10] .
TGF-binds to a heteromeric cell-surface complex consisting of two type II and two type I transmembrane receptor serine/threonine kinases in which ligand binding induces phosphorylation and activation of the type I receptors by the type II receptor kinases 11, 12 . Signaling is mediated in part by Smad proteins which are activated directly by the TGF-type I receptor kinase by phosphorylation on their C-terminus and then translocate to the nucleus in complex with the common mediator Smad4 to regulate transcription of target genes. The principal receptor-activated Smads involved in signaling from TGF-receptors are Smad2 and Smad3. In the nucleus, Smad For personal use only. on April 12, 2017. by guest www.bloodjournal.org From
Materials and Methods

Cell culture and induction of differentiation
The HL-60 cells (American Type Culture Collection, Rockville, MD) and HL-60R cells resistant to retinoic acid induced differentiation (a gift of Steve Collins, Fred Hutchinson Cancer Center, Seattle WA) were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin, 100µg/ml streptomycin, 4.0 mM glutamine, nonessential amino acids, 10 mM HEPES buffer (Life Technologies, Inc., Gaithersburg, MD). Experiments were carried out in the same medium supplemented with 5% fetal bovine serum. Differentiation was induced by exposing 3-5× 10 5 cells/ml to 10 nM ATRA (Sigma, St Louis, MO), 10 ng/ml TGF-1 (a kind gift of R&D Systems, Inc., Minneapolis, MN), or 10 nM ATRA+ 10 ng/ml TGF-1 or 100 nM Vit D 3
(Roche Co., Basel, Switzerland) for the indicated time periods. For determination of cell morphology, cytospins were made following 4 days of culture with the various treatments, and slides were stained with Wright's Giemsa and photographed at ×400 magnification. PD98059 (Cell Signaling Technology, Inc., Beverly, MA) was diluted from a 2mM stock in DMSO and added to cells 2 hrs prior to addition of TGF-or ATRA. TGF-control (12H5) or neutralizing(1D11)
antibodies (Genzyme Diagnostics, Cambridge, MA) were used at 30 µg/ml. In the experiments in Burlingame, CA) and examined using a confocal immunofluorescence microscope.
Reverse transcriptase (RT)-PCR assays
Total RNA was extracted from HL-60 cells cultured with various inducing agents for different periods of time using TRIzol Reagent (Life Technologies, Inc.). cDNA was synthesized using 1µg of total RNA primed with oligo d(T) in 50µl reactions. To test for contamination by genomic DNA, additional reactions were done without adding reverse transcriptase. The resulting total cDNA was then used in the PCR to measure the mRNA levels of Smads using primers as described below, the mRNA level of GAPDH was used as internal control. Linear amplification cycles were determined separately for each Smad as published elsewhere 27 .
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Western blot analysis
Western Blot analysis was performed as described previously 26 . Briefly, cells were lysed in 0.5 ml of Triton X-100 lysis buffer (25mM HEPES at pH 7.5, 150mM NaCl, 10% glycerol, 5mM EDTA, 
TGF-1 induces the phosphorylation and nuclear accumulation of endogenous Smad2/3
The phosphorylation of Smad2 on Ser465/467 and subsequent dimerization with Smad4 and translocation to the nucleus are known to be required for signal transduction by the TGFreceptor, leading to the transcriptional activation of target genes 13 Figure 5c , the TGF-1 neutralizing antibody 1D11 blocked both Vit D 3 -and TGF--induced phosphorylation of Smad2, while the control antibody had no effect. To ascertain that the effects of the blocking antibody on Smad2 phosphorylation paralleled effects on differentiation, we assessed the functional activity of HL-60 cells 6 days after treatment with Vit D 3 or TGF-, using the NSE assay for monocytic differentiation and the reduction of NBT as 
ATRA increases dephosphorylation of Smad2
Since ATRA decreases levels of phospho-Smad2/Smad3 and reduces the number of cells with nuclear staining for Smad2/Smad3 in cells treated with TGF-1, we investigated whether preexposure of HL-60 cells to ATRA or TGF-1 would affect the subsequent ability of these agents to activate Smad2. HL-60 cells were incubated for 2 days in the presence of either TGF-1 or ATRA or the combination, washed to remove these effectors, and then incubated with a different factor for another 24 hr prior to analysis of the levels of phospho-Smad2 (Figure 7a ). These experiments showed that the level of phospho-Smad2 in cells that had been treated with TGF-1 for 2 days was lower when that treatment was followed by addition of ATRA for 24 hours, than when cells were treated for the final 24 hours with only control medium. As before, there was no change in the expression level of total Smad2. We interpreted these data to suggest that treatment with ATRA actively reduced the level of existing phospho-Smad2 in cells previously treated with TGF-1.
To address possible mechanisms whereby ATRA might decrease levels of phospho-Smad2/3 in cells treated with TGF-1, we investigated whether either proteasome-mediated degradation of phospho-Smad 32 or phosphatase-mediated dephosphorylation might be involved. Addition of the (Figure 7c) . Surprisingly, treatment of the cells with okadaic acid alone, resulted in detectable phospho-Smad2, though at levels lower than that observed by treatment of the cells with TGF- (Figure 7d ).
Together, these data suggest that endogenous protein serine-threonine phosphatases likely control the basal level of phospho-Smad2 and that ATRA reduces levels of phospho-Smad2 through induction of such phosphatases.
We then assessed the effect of okadaic acid on the differentiation of HL-60 cells treated with ATRA, TGF-, or both to test the hypothesis that induction of the putative serine/threonine phosphatase would favor granulocytic differentiation and that inhibition of serine/threonine phosphatase activity would shift the balance towards monocytes. As shown in Table 3 , treatment of HL-60 cells with ATRA for 2 days followed by incubation for an additional 2 days with 2.5 nM okadaic acid increased expression of both CD14 and NSE activity, and decreased expression of CD15, compared to cells treated with only ATRA. Okadaic acid also strongly enhanced the ability of TGF-to induce differentiation to functional monocytes and, when added for the second two days to cells treated with the combination of ATRA and TGF-, reduces the expression of CD15 and enhances expression of both CD14 and NSE activity. These data show that okadaic acid enhances the proportion of HL-60 cells expressing monocytic features, independently of the presence of other differentiating agents, and consistent with its effects on phospho-Smad2 ( Figure   For 
-18-7c,d). When cells are treated with both ATRA and TGF-, which results in reduced nuclear phospho-Smad2/3 compared to that in cells treated with TGF-alone (Figures 2,3) , the addition of okadaic acid inhibits the ATRA-dependent suppression of Smad2/3 phosphorylation (Figure 7c) simultaneous with its skewing the differentiation towards monocytes ( Table 3 ).
The ability of ATRA to decrease levels of phospho-Smad2/3 is dependent on RAR To further address the mechanism whereby ATRA modulates the levels of phospho-Smad2 and to link these effects to the ability of ATRA to induce granulocytic differentiation of HL-60 cells, we For
Discussion
This study provides new insights into mechanisms whereby hematopoietic cells interpret and integrate the multiplicity of extracellular signals that ultimately specify distinct lineage decisions.
Using the model system of HL-60 cells, a human myeloblastic leukemia with promyelocytic features, we have shown that the interplay of signals from ATRA which specifies differentiation to granulocytes, or TGF-1/ Vit D 3 , which specify commitment to monocytic differentiation, is mediated, in part, through a balance between protein serine/threonine phosphatase activity and levels of phosphorylated Smad2 and Smad3. Thus we have shown that TGF-1 induces phosphorylation of Smad2/3 and that addition of ATRA together with TGF-1, reduces the level of phospho-Smad2/3 and increases the extent of commitment to the granulocytic lineage at the expense of the monocytic lineage. Conversely, okadaic acid, which inhibits protein serine/threonine phosphatases and which enhances the level of phospho-Smad2/3 in cells, pushes the balance toward monocytic differentiation. Together these data suggest that monocytic differentiation is favored by lower protein phosphatase activity and/or increased levels of nuclear Smad2/3 (if the inducing agents are TGF-or Vit D3) and that granulocytic differentiation is favored by higher protein phosphatase activity and/or reduced nuclear Smad2/3. In the specific case where ATRA and either TGF-or Vit D3 are acting on the cell simultaneously, the data suggest that the induction of protein serine/threonine phosphatase activity by ATRA can modulate the levels of phospho-Smad2/3 induced by TGF-and thereby alter the partitioning between the granulocytic and monocytic pathways.
Signal transduction pathways are regulated by dynamic interplay between protein kinases and phosphatases. Numerous reports have examined the ability of ATRA to alter phosphatase activity 36 , which are predicted to result in a change in substrate specificity, which are most likely to affect levels of phospho-Smads at these times, as observed (Figure 7b ). The ability of okadaic acid to induce both phenotypic and functional attributes of monocytes (Table 3) and to enhance For For Smad-specific primer pairs were selected from the corresponding cDNA sequence information obtained from the NIH database as indicated under Materials and Methods. Primer pairs were used to amplify Smad specific fragments from reverse transcribed total RNA isolated from the indicated samples as template. 1 µg total RNA, quantified by spectrophotometry and agarose gel analysis, was used for reverse transcription in all cases. Smad2, Smad3, Smad4, Smad7 and GAPDH (as a internal control) were amplified by PCR and analyzed on an agarose gel. For personal use only. on April 12, 2017. by guest www.bloodjournal.org From 
